Tax-driven share sale follows PSU vesting at Travere (TVTX)
Rhea-AI Filing Summary
Travere Therapeutics’ chief commercial officer Peter Heerma reported a mix of equity award vesting and a required tax-related sale. On May 4, 2026, 4,250 performance-based restricted stock units (PSUs) vested, converting into 4,250 shares of common stock after Travere confirmed a FILSPARI cumulative net revenue performance milestone tied to results for the quarter ended March 31, 2026.
Those PSUs are part of an 8,500-unit grant awarded on January 31, 2024, with an additional 25% scheduled to vest on January 31, 2027, contingent on continued service. The filing notes that up to 50% additional shares could vest later if certain milestones are achieved on an accelerated timeline. On May 5, 2026, Heerma sold 2,174 shares at $46.65 per share to cover tax withholding obligations under a mandatory “sell to cover” arrangement chosen by the company, described as a non-discretionary sale. After these transactions, he directly holds 140,684 shares of Travere common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 2,174 | $46.65 | $101K |
| Grant/Award | Performance-based restricted stock units | 8,500 | $0.00 | -- |
| Exercise | Performance-based restricted stock units | 4,250 | $0.00 | -- |
| Exercise | Common Stock | 4,250 | $0.00 | -- |
Footnotes (1)
- On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions.
Key Figures
Key Terms
performance restricted stock units financial
PSUs financial
sell to cover financial
cumulative FILSPARI net revenue financial
equity incentive plans financial
AI-generated analysis. How Rhea-AI works. Not financial advice.